Perrigo Company plc · NYSE:PRGO
Perrigo — Deutsche Bank Healthcare Conference 2009
20 slides from Perrigo's conference presentation, May 18, 2009
Slide 1: Deutsche Bank Healthcare Conference May 18, 2009
Deutsche Bank Healthcare Conference May 18, 2009
Slide 2: Forward Looking Statements
Forward Looking Statements Certain statements in this presentation are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company’s future
Slide 3: Perrigo Financial Performance
Perrigo Financial Performance -From Continuing Operations 2,000 • Top line growth fueled by 1,800 16% $1,730 both organic and inorganic R = 1,600 C AG 08 $1,499 activities 03 - 20 20 $1,368 Q408 1,400 $1,294 • FY’08 revenue increased 1,200 $362 million, or 26% $1,007 1,000 $898 $834 • FY’08 new prod
Slide 4: Broad Manufacturing Scale
Broad Manufacturing Scale Facilities Solid dose Liquids Semi-Solids API North 9 Plants 32 Billion Tablets 170 Million Units 60 Million Units America Europe 3 Plants 3 Billion Tablets 65 Million Units 400 tons Middle/ 5 Plants 0.5 Million Tablets 2 Million Units 6 Million Units 450 tons Far East Tota
Slide 5: Consumer Healthcare
Consumer Healthcare Global Sales of over $1.3 Billion KEY GROWTH DRIVERS • Mass customization Revenue ($ Mill) QUARTERLY PERFORMANCE • Leader Rx to OTC switches $500 • 48 ANDA’s in pipeline $450 • Famotidine Complete $400 $350 • Generic Omeprazole $300 FY'06 FY'07 • Generic Cetirizine $250 FY'08 $20
Slide 6: Magic of Store Brands
Magic of Store Brands Store Brands provide consumer value while driving retailer profitability National Store Brand Brand Consumer Price $10.00 $7.00 Retail Cost 7.50 3.00 Retail Profit $2.50 $4.00 % Profit 25% 57% Consumer Savings 30% 5
Slide 7: Store Brands Drive Retailer Profit
Store Brands Drive Retailer Profit Contribution of Store Brand to a Retailer’s Total Category Sales ($) Vol (Units) Profit ($) 90 80 70 Percent 60 50 40 30 20 10 0 Analgesics Cough/Cold Vitamins Smoking 6 Cessation
Slide 8: Perrigo is the Clear Leader in Rx to OTC Switch
Perrigo is the Clear Leader in Rx to OTC Switch • 61 approvals over the past 30 years Other • Switch Experts: more ANDAs than any OTC Perrigo Participates in 70% of Market company Nearly $10B potential Rx switches in the next 5 years 7
Slide 9: New Products Drive Growth
OiGpr ad ole delayed release tablets 20, Just One Tablet Prevents & Relieves Heartbum Due to Acid Indigestion Negi um Smoking Aid Stop Smoking Aid PERHIGD = CENTURY ‘High Potency Multtamin/Multinineal Supplement Glucosamine Cone
Slide 10: Power of Perrigo—The Cetirizine Launch
Power of Perrigo— The Cetirizine Launch On-shelf Bonus & Economy signage Sizes Pharmacy Store Brand Market Share Introduction Kits Brand Promotion Drives 20% Store Brand Awareness 80% Print Ads Perrigo Other Off-shelf Displays 9
Slide 11: Store Brand Cetirizine 10MG Volume Share
Store Brand Cetirizine 10MG Volume Share - FDMx 60.0% 50.0% 50.7% 49.0% 50.0% 47.4% 47.3% 45.9% 46.0% 43.8% 42.0% 42.6% Volume Share 38.5% 40.0% 37.7% 35.6% 30.0% 27.0% 20.0% 12.6% 10.0% 0.0% 4 Week 4 Week 4 Week 4 Week 4 Week 4 Week 4 Week 4 Week 4 Week 4 Week 4 Week 4 Week 4 Week 4 Week 4 Week End
Slide 12: Power of Perrigo – The Omeprazole Launch
Power of Perrigo – The Omeprazole Launch • Brand Sales $750M+ • Potential Annual Revenue Of $150 – 200M 11
Slide 13: Perrigo Store Brand Omeprazole Volume Share
Perrigo Store Brand Omeprazole Volume Share - FDMx 45.0% 40.3% 39.4% 40.0% 38.5% 36.2% 36.8% 35.8% 34.5% 34.7% 33.9% 35.0% 31.2% 30.8% 30.0% 27.5% Volume Share 25.0% 22.0% 20.0% 15.0% 10.0% 4.1% 5.0% 0.0% 4 Week 4 Week 4 Week 4 Week 4 Week 4 Week 4 Week 4 Week 4 Week 4 Week 4 Week 4 Week 4 Week 4 We
Slide 14: All Category Update
All Category Update Category Dollar % Growth National Brand Dollar % Growth Store Brand Dollar % Growth Total OTC & Nutrition 3.5 Total OTC & Nutrition 0.6 Total OTC & Nutrition 13.3 OTC 2.4 OTC -1.3 OTC 15.9 Analgesics -0.2 Analgesics -2.3 Analgesics 6.4 CCAS 5.4 CCAS 2.4 CCAS 17.5 GI 0.4 GI -6.2 G
Slide 15: Wal-Mart $4 Rollback Program
Wal-Mart $4 Rollback Program • World’s largest retailer promoting OTC Store Brand • Focus on quality, affordable healthcare • Expectations for increased volume • Similar to Generic Rx program 14
Slide 16: Generic Rx Business
Generic Rx Business Top 2 Topical Player QUARTERLY PERFORMANCE KEY GROWTH DRIVERS Rev. (Millions) • Top 2 player in topicals $50 • High barrier to entry – $45 clinical endpoints $40 $35 • FY’08 Sales of $161 million FY'06 $30 FY'07 • Key new products $25 FY'08 - Nasacort settlement $20 FY'09 - Olux
Slide 17: Active Pharmaceutical Ingredients
Active Pharmaceutical Ingredients Rev. QUARTERLY PERFORMANCE KEY GROWTH DRIVERS (Millions) $40 • One of the world’s largest API businesses $35 • Selling to Pharma companies $30 in more than 25 countries FY'06 $25 FY'07 • FY’08 Sales of $150 million $20 FY'08 $15 FY'09 • Focus on complex, differentia
Slide 18: Perrigo – Continually investing in R&D
Perrigo – Continually investing in R&D Leading Indicator = Growth $85 M illio n s $65 $45 $25 2004 2005 2006 2007 2008 2009E 17
Slide 19: Fiscal 2009 and Future Growth Drivers
Fiscal 2009 and Future Growth Drivers Growth Corrective Pressures Action Increased Contract Manufacturing Sales Ibuprofen PM - $70MM Brand Sales Nutrition and Pricing Action Acquisitions – Diba, JB Labs, OTC Input to Restore and Unico Pricing improve Famotidine Complete - $90MM Pressure Margins Bran
Slide 20: Perrigo Uniquely Positioned
Perrigo Uniquely Positioned • Critical Mass in the industry – 35+ billion tablets/caplets per year • Mass customization – 10,000+ SKUs • Focus on Generic Rx topicals with significant barriers to entry • Low cost manufacturing • API business provides vertical integration potential and critical purcha
Perrigo Company — Deutsche Bank Healthcare Conference 2009 on 6ix